Xenon Pharmaceuticals Inc. Share Price
XENEXenon Pharmaceuticals Inc. Stock Performance
Open $41.87 | Prev. Close $41.26 | Circuit Range N/A |
Day Range $40.48 - $42.19 | Year Range $26.74 - $46.50 | Volume 68,645 |
Average Traded $41.05 |
Xenon Pharmaceuticals Inc. Share Price Chart
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Jan-26 | $41.87 | $40.98 | +0.00% |
06-Jan-26 | $41.87 | $40.98 | -1.86% |
05-Jan-26 | $44.13 | $41.75 | -6.24% |
02-Jan-26 | $44.46 | $44.53 | -0.62% |
31-Dec-25 | $44.15 | $44.81 | +1.53% |
30-Dec-25 | $44.26 | $44.13 | -0.39% |
29-Dec-25 | $44.36 | $44.31 | -0.98% |